Title: Co-director of oncology research, HealthPartners Institute, and investigator, Metro-Minnesota Community Oncology Research Consortium
Park Nicollet Frauenshuh Cancer Center title: Medical oncologist and hematologist
Education and training: MD, University of Chicago, Pritzker School of Medicine; internal medicine residency and fellowship in hematology, oncology and transplantation, University of Minnesota; master’s degree in clinical research, University of Minnesota.
Overview/research interests: Dr. Lerner is co-director of oncology research at HealthPartners Institute, where she has been a principal investigator on industry-sponsored research studies in both oncology and hematology. She is also an investigator for the Metro-Minnesota Community Oncology Program and is the site principal investigator for several Gynecology Oncology Group clinical trials. Dr. Lerner has written or co-written manuscripts on cancer treatment symptom management, cancer survivorship, vitamin D in breast cancer and non-Hodgkin’s lymphoma.
Dr. Lerner is interested in providing access for patients to clinical research trials testing new treatments or improving quality of life. In addition, her interests include cancer survivorship, quality improvement and health care delivery. She has ongoing collaborations with HealthPartners investigators in the implementation and assessment of a neutropenia risk assessment and electronic clinical decision support system, the effects of vitamin D3 on ai-associated musculoskeletal symptoms in women with early breast cancer and the treatment of non-melanoma skin cancer in patients with limited life expectancy. She is active in the development and assessment of the cancer survivorship program.
Current research activities and funding:
- Site principal investigator, MK3475: A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Site principal investigator, ACE-CL-006: A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196Versus Ibrutinib in Previously Treated Subjects with High-Risk Chronic Lymphocytic Leukemia